 There is no coherent picture of resistance mutations associated with treatment failure. 
analogue ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) has been the standard of care for treatment of chronic HCV infections for over a decade [4] [5] [6] . Only about 60% of treated patients show a sustained viral response (SVR) to standard of care 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 3 treatment, and several host and viral factors appear to contribute to treatment efficacy [7, 8] .
The availability of several directly acting antiviral agents (DAAs) for HCV -mainly inhibitors of NS3 (protease), NS5A and NS5B (polymerase) [9] [10] [11] [12] SVR rates when IFN is included together with DAAs in therapy [13, 14] .
Experience gained with other viral diseases, particularly HIV-1 infections,
anticipates that resistance to DAAs may unfold and result in the successive incorporation of new inhibitors in therapy, with waves of standard and salvage treatments, unless virus elimination from chronically infected patients is widespread (as a result of new treatments available worldwide). Particularly difficult cases that may require IFN-based treatments are HIV-1 coinfected patients, infections by certain HCV genotypes or subtypes, and patients with advanced liver fibrosis. If IFNs remain components of some treatment protocols, HCV IFN resistance will remain a factor of treatment failure. Unfortunately, IFN resistance is proving a far more complex issue than DAA resistance, due to both physiological and evolutionary reasons.
DAA-and IFN-escape mutants
For antiviral compounds that target a specific viral protein, a number of amino acid substitutions that mediate different degrees of resistance to the corresponding antiviral compound are often identified consistently in the target protein. They can be catalogued   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   4 and ideally their presence -either as dominant genomes or in minority components of the mutant spectrum-can be taken into consideration for treatment planning. [19] . 
Viral fitness and IFN-escape
An additional difference between resistance to DAAs and to IFN is the effect of fitness enhancing mutations on the resistance phenotype. The ease of selection of a DAA resistance mutation depends on the genetic barrier (number of mutations required to attain the amino acid substitutions needed) and the phenotypic barrier to resistance (or fitness cost inflicted by the required amino acid substitutions) [20] . A DAA-resistance mutation may be selected prior to or together with accompanying mutations that compensate for fitness Viral quasispecies evolve by replacement of subpopulations of mutant swarms by others present or arising in the same replicative ensemble [20] . Most HCV subpopulations that may increase in frequency as a result of mutations that decrease the sensitivity to some ISG products will nevertheless face the limitation of having to replicate in the presence of other ISG products. That is, their fitness advantage in such a milieu will be minimal. This means that unless multiple mutations that would confer resistance to the majority of ISG products and other innate response elements occur in the HCV genome -unlikely because they would require accessing remote regions of sequence space [20] -no subpopulation will reach dominance. Partially selected swarms will still be vulnerable to suppression by the mutant spectrum that surrounds them [21] [22] [23] [24] [25] [26] ). If such frequency-enhanced populations were displaced and remained at memory levels [27] their proportion and duration in the population would be limited [28] [29] [30] . Thus, the environmental complexity confronted by HCV renders unlikely that specific mutations can be identified as consistently conferring an IFN-resistant phenotype.
Host and viral factors in IFN resistance
Based on the dynamics of viral quasispecies, we hypothesize that the broader the antiviral response evoked by an agent such as IFN, the more host factor-dependent will the response be. Signalling pathways and metabolic routes that participate in the IFN-mediated antiviral state may vary in their activity depending on allele composition. Variation at the Other polymorphisms (i.e. KIR2DS [33] ) and several host traits (sex, age, ethnic origin, obesity, insulin resistance, ethanol consumption, HIV-1 infection, degree of liver fibrosis, etc.) have been associated with the response to IFN [16, 34] . Patients whose endogenous IFN system is activated are poor responders to IFN-α based treatments (reviewed in [16] ).
These host influences are interconnected with viral factors which include genotype, viral load, quasispecies complexity and predominant mutations types in mutant spectra [20,35 • ].
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[55] (NS5A substitution T104A in Figure 1 ). In the 3a/JFH1 chimera, substitutions F345V
(in E1), H837Y (in NS2) and T2076A (in NS5A) (numbering according to Serre et al. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10 Thus, IFN resistance is an extremely complex issue, and the patterns of resistance development deviate from a direct mutation-competition-selection pattern readily identifiable with inhibitors that target a defined viral genomic structure or protein.
Concluding remarks
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